Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Triple-Drug combo aims to lower blood pressure better in seniors

NCT ID NCT06041529

Disease control Sponsor: Yuhan Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new fixed-dose combination pill containing three blood pressure medicines (telmisartan, amlodipine, and chlorthalidone) against another triple combination (with hydrochlorothiazide instead of chlorthalidone) in elderly patients whose blood pressure is not well controlled. About 198 participants aged 65 and older will take one of the two combinations for up to 26 weeks. The main goal is to see which pill better lowers nighttime blood pressure, with safety monitored throughout.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

198 people

The number who actually took part.

Started

Oct 2023

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants who have been fully informed about the purpose, content, and characteristics of investigational product, and have voluntarily agreed in writing 2. Aged ≥ 65 with essential hypertension 3. Patient with uncontrolled essential hypertension at screening * If already taking antihypertensive drugs, mean sitting systolic blood pressure (MSSBP) must be 140 mmHg ≤ MSSBP \< 200 mmHg * If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (MSSBP) must be 160 mmHg ≤ MSSBP \< 200 mmHg Exclusion Criteria: 1. Patient who has history of drug allergic reactions 2. Known hypersensitivity to components of the investigational product 3. Patient who is unable to stop taking prohibited drugs 4. Test results showing the following values at screening * The change of MSSBP ≥ 20 mmHg and MSDBP ≥ 10 mmHg on target arm between 1st and 2nd measurements 5. Pregnant or lactating women 6. Patient who is unable to maintain proper night sleep 7. Malnutrition, starvation, debilitating factors, A person who is being forcibly detained for the treatment of mental or physical 8. Administration of other investigational products within 3 months prior to screening. 9. An impossible one who participates in clinical trial by investigator's decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential hypertension

Contacts and locations

Locations

  • Chonnam National University Hospital

    Gwangju, 61469, South Korea

  • Gwangju Veterans Hospital

    Gwangju, 62284, South Korea

  • Hanyang university medical center

    Seoul, 04763, South Korea

  • Korea University Guro Hospital

    Seoul, 08308, South Korea

  • Pusan National University Yangsan Hospital

    Busan, 50612, South Korea

  • Seoul national University Budang hospital

    Seoul, 13620, South Korea

  • The Catholic University of Korea Bucheon St.Mary's Hospital

    Seoul, Gyeonggi-do, 14647, South Korea

  • The Catholic University of Korea Daejeon ST. Mary's Hospital

    Daejeon, 34943, South Korea

  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital

    Seoul, 03312, South Korea

  • The Catholic University of Korea, Incheon ST. Mary's Hospital

    Incheon, 21431, South Korea

  • The Catholic University of Korea, ST. Vincent's Hospital

    Gyeonggi-do, 16247, South Korea

  • The Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul, 06591, South Korea

  • The Catholic University of Korea, Uijeongbu ST. Mary's Hospital

    Seoul, 11765, South Korea

  • The Catholic University of Korea, Yeouido ST. Mary's Hospital

    Seoul, 07345, South Korea

  • Wonju Severance Christian Hospital

    Wŏnju, Gangwon-do, 26426, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.